On March 5, 2026, the FDA approved a new combination therapy pairing the bispecific antibody teclistamab (Tecvayli) with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior line of treatment. The approval, granted to Janssen Biotech, was based on striking clinical trial results showing an 83 percent reduction in the risk of disease progression or death compared to standard treatment. For families navigating both cancer and cognitive decline — and the overlap is more common than many realize — this represents a meaningful shift in how aggressively and effectively relapsed blood cancers can now be treated without the prolonged, grueling regimens that once defined the standard of care.
This approval also converted teclistamab’s earlier accelerated approval as a standalone therapy into a full, traditional approval, signaling that the FDA now considers the drug’s benefits firmly established. The agency processed the application in just 55 days under its National Priority Review Voucher pilot program, a pace that underscores how compelling the clinical data were. For older adults and their caregivers — particularly those managing multiple myeloma alongside dementia or other neurological conditions — the rapid expansion of bispecific antibody options is worth understanding, especially given the unique side effect profile these therapies carry. This article covers what the new approval means in practical terms, how teclistamab compares to other bispecific antibodies now on the market, what the clinical trial showed, and what caregivers should know about the neurological side effects that make these drugs particularly relevant to the brain health community.
Table of Contents
- What Is the New Bispecific Antibody Approved for Relapsed Multiple Myeloma?
- What Did the MajesTEC-3 Trial Actually Show?
- Why Brain Health Advocates Should Pay Attention to Bispecific Antibody Side Effects
- How Does Teclistamab Compare to Other Approved Bispecific Antibodies for Myeloma?
- The Hidden Challenge of Managing Myeloma Treatment in Patients with Cognitive Decline
- What Is Coming Next in the Bispecific Antibody Pipeline?
- The Convergence of Cancer Immunotherapy and Neuroscience Research
- Conclusion
- Frequently Asked Questions
What Is the New Bispecific Antibody Approved for Relapsed Multiple Myeloma?
Teclistamab is a bispecific antibody, meaning it is engineered to grab onto two different targets simultaneously. One arm binds to BCMA (B-cell maturation antigen), a protein found on the surface of myeloma cells, while the other arm latches onto CD3, a receptor on T cells. By physically bridging a cancer cell and an immune cell, teclistamab essentially forces the body’s own immune system to recognize and destroy the tumor. The newly approved combination adds daratumumab hyaluronidase-fihj — itself an established myeloma drug that targets CD38 — to attack the cancer through a second, complementary mechanism. The practical significance here is the broadened eligibility.
When teclistamab first received accelerated approval in October 2022, it was restricted to patients who had already failed at least four prior lines of therapy — a late-stage, heavily pretreated population with very limited options. The March 2026 approval moves the combination up to patients who have tried just one prior regimen that included a proteasome inhibitor and an immunomodulatory agent. That is a substantially larger group of patients, and it means the drug is now available much earlier in the disease course, when patients are generally stronger and better able to tolerate treatment. To put this in context, consider a 72-year-old patient with myeloma whose disease returned after initial treatment with lenalidomide and bortezomib. Under previous guidelines, bispecific antibodies would not have been an option until that patient had cycled through several more lines of chemotherapy. Now, the teclistamab-daratumumab combination can be offered as a second-line therapy — a change that could spare months or years of additional treatment burden.
What Did the MajesTEC-3 Trial Actually Show?
The approval rested on the MajesTEC-3 trial, a randomized, open-label study that enrolled 587 patients with relapsed or refractory multiple myeloma. Of those, 291 received the teclistamab-daratumumab combination while 296 received the control regimen. The headline result was dramatic: median progression-free survival in the combination arm had not yet been reached at the time of analysis, compared to 18.1 months in the control group. The hazard ratio was 0.17, corresponding to that 83 percent reduction in the risk of progression or death, with a p-value below 0.0001. The response rates were equally striking. Nearly 89 percent of patients in the combination arm responded to treatment, compared to 75.3 percent in the control group.
More importantly, the depth of those responses was far superior — 81.8 percent of patients in the combination arm achieved a complete response or better, versus 32.1 percent in the control group. Minimal residual disease negativity at a sensitivity of one in 100,000 was achieved by 58.4 percent of patients receiving the combination, compared to just 17.1 percent in the control arm. These are the kinds of numbers that prompted the FDA to grant Breakthrough Therapy Designation back on December 9, 2025. However, it is important to note that “not reached” for median progression-free survival does not mean the drug cures myeloma. It means that at the time the data were analyzed, more than half of the patients in the combination arm had not yet experienced disease progression — but longer follow-up will be needed to know the true median. Myeloma remains, for the vast majority of patients, a disease that will eventually return. Families should understand that even a remarkable treatment like this one is buying time, potentially a great deal of it, but not offering a definitive cure for most patients.
Why Brain Health Advocates Should Pay Attention to Bispecific Antibody Side Effects
The boxed warning on teclistamab’s label flags two serious risks that are directly relevant to anyone in the dementia care or brain health space: cytokine release syndrome and neurotoxicity, specifically immune effector cell-associated neurotoxicity syndrome, or ICANS. CRS occurs when the activated T cells release a flood of inflammatory molecules, causing fever, low blood pressure, and in severe cases organ failure. ICANS can produce confusion, difficulty speaking, tremor, seizures, and altered consciousness — symptoms that can be difficult to distinguish from dementia-related cognitive decline in older adults. This overlap creates a real clinical challenge. A caregiver managing a parent with both myeloma and mild cognitive impairment may struggle to tell whether a new episode of confusion is a medication side effect, a progression of underlying dementia, or something else entirely.
In the LINKER-MM1 trial for the newer bispecific linvoseltamab, neurotoxicity including ICANS occurred in 54 percent of patients, and CRS in 46 percent. These are not rare events. They require close monitoring, typically in an inpatient setting for the initial doses, and clear communication between the oncology team and any neurologists or geriatricians involved in the patient’s care. For families already dealing with cognitive decline, the key takeaway is not that bispecific antibodies should be avoided — the survival benefits are too significant for that — but that proactive neurological monitoring needs to be part of the treatment plan from day one. Any baseline cognitive testing should be completed before treatment starts, so that changes can be measured against a known starting point rather than guessed at after the fact.
How Does Teclistamab Compare to Other Approved Bispecific Antibodies for Myeloma?
As of March 2026, the FDA has approved four bispecific antibodies for relapsed or refractory multiple myeloma. Three of them — teclistamab, elranatamab (Elrexfio, approved August 2023), and linvoseltamab (Lynozyfic, approved July 2025) — all target BCMA and CD3. The fourth, talquetamab (Talvey, also approved August 2023), takes a different approach by targeting GPRC5D instead of BCMA. This distinction matters because patients whose myeloma has already been treated with a BCMA-directed therapy may benefit from switching to a GPRC5D-targeting drug, or vice versa. The practical tradeoff between these options often comes down to dosing convenience and side effect profiles.
Linvoseltamab, the most recently approved single-agent option, has a notable advantage in scheduling: it is the first BCMA-targeting bispecific approved for every-two-week dosing starting at week 14, and patients who achieve a very good partial response or better after 24 weeks can shift to once-monthly dosing. For older patients or those with caregiving responsibilities, fewer clinic visits can make a meaningful difference in quality of life. By comparison, teclistamab as monotherapy requires weekly dosing, though the combination with daratumumab may alter the treatment calendar. Response rates across these drugs are not directly comparable because they were studied in different trials with different patient populations. Linvoseltamab showed an overall response rate of 70 percent in a heavily pretreated population with a median of four or more prior lines of therapy, while the teclistamab-daratumumab combination achieved 89 percent in patients with fewer prior treatments. The takeaway is not that one drug is universally better, but that the choice depends heavily on where a patient is in their treatment journey, what they have already received, and how they weigh efficacy against logistical and neurological burden.
The Hidden Challenge of Managing Myeloma Treatment in Patients with Cognitive Decline
One of the most underappreciated complications in oncology is managing complex treatment regimens in patients who also have dementia or significant cognitive impairment. Bispecific antibodies require careful step-up dosing schedules, regular monitoring for CRS and ICANS, and prompt reporting of symptoms — all of which assume a level of patient engagement and self-advocacy that dementia progressively erodes. A patient with moderate Alzheimer’s disease may not be able to articulate that they are experiencing the early signs of cytokine release syndrome, such as chills, muscle aches, or a low-grade fever. This is where caregiver preparedness becomes not just helpful but medically necessary.
Caregivers should work with the oncology team to establish a clear protocol: what symptoms to watch for in the first 48 hours after each dose, when to call the clinic versus when to go directly to the emergency department, and how to document any changes in cognitive function that might indicate ICANS rather than dementia progression. Written checklists, medication calendars, and a designated family contact for the oncology team are all practical tools that reduce the margin for error. It is also worth acknowledging a harder conversation: not every patient with advanced dementia is a good candidate for aggressive myeloma treatment. The decision to pursue bispecific antibody therapy involves weighing the genuine survival benefit against the patient’s overall quality of life, their ability to tolerate monitoring, and the burden on caregivers. These are deeply personal decisions with no universal right answer, and they deserve honest, unhurried discussion with the medical team rather than reflexive pursuit of the newest available therapy.
What Is Coming Next in the Bispecific Antibody Pipeline?
The pipeline is active. LBL-034, a bispecific T-cell engager targeting GPRC5D and CD3, has received FDA Fast Track Designation for relapsed or refractory multiple myeloma based on promising early-phase data from a study conducted in China. If approved, it would be the second GPRC5D-targeting bispecific on the market, giving oncologists another option for patients whose disease has progressed on BCMA-directed therapies.
The broader trajectory is unmistakable. The American Society of Clinical Oncology has updated its multiple myeloma treatment guidelines, citing what it calls a “massive shift” driven by bispecific antibodies and other immunotherapies. For caregivers in the brain health community, this shift means that myeloma — once a disease with limited options after relapse — is increasingly becoming a chronic condition that can be managed over years rather than months. That is a fundamentally different planning horizon for families already navigating long-term cognitive decline.
The Convergence of Cancer Immunotherapy and Neuroscience Research
One underexplored dimension of the bispecific antibody revolution is what it may eventually teach us about the brain. The neurotoxicity associated with these drugs, while clearly a serious side effect, is also generating an unprecedented volume of clinical data on how immune activation affects cognition. Researchers studying ICANS are learning about the inflammatory pathways that disrupt the blood-brain barrier and cause neurological symptoms — pathways that overlap significantly with those implicated in Alzheimer’s disease and other forms of neurodegeneration.
This does not mean that myeloma drugs will treat dementia. But the scientific cross-pollination is real. As oncologists develop better tools to predict, prevent, and manage ICANS, some of that knowledge may inform neuroinflammation research more broadly. For families living at the intersection of cancer and cognitive decline, the progress in one field may eventually benefit the other in ways that are difficult to predict but worth watching.
Conclusion
The FDA’s March 2026 approval of teclistamab in combination with daratumumab marks a significant expansion of treatment options for adults with relapsed multiple myeloma, offering an 83 percent reduction in the risk of disease progression with response rates approaching 90 percent. Combined with three other approved bispecific antibodies and a growing pipeline, the treatment landscape for myeloma has shifted decisively toward immunotherapy-based approaches that would have been unimaginable a decade ago. For older adults and their families, this translates to more options, earlier access, and the realistic possibility of longer, more stable periods of disease control.
For caregivers in the brain health community, the practical message is twofold. First, these therapies work, and patients with myeloma should not be denied access simply because they also have cognitive concerns. Second, the neurological side effects are real and require proactive management, especially in patients with pre-existing dementia or cognitive impairment. The best outcomes will come from coordinated care between oncology and neurology teams, clear communication with caregivers, and honest conversations about goals of treatment that account for the whole patient — not just the cancer.
Frequently Asked Questions
What is a bispecific antibody and how does it treat multiple myeloma?
A bispecific antibody is an engineered protein with two binding arms — one that attaches to a target on cancer cells (such as BCMA) and another that grabs onto T cells (via CD3). By physically linking an immune cell to a myeloma cell, it directs the immune system to destroy the cancer. Four bispecific antibodies are now FDA-approved for relapsed or refractory multiple myeloma as of March 2026.
Who is eligible for the new teclistamab-daratumumab combination?
Adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. This is a broader group than the original teclistamab monotherapy approval, which required four or more prior lines of treatment.
What are the most serious side effects of bispecific antibodies for myeloma?
Cytokine release syndrome and neurotoxicity (ICANS) are the most significant risks, both carrying a boxed warning. CRS involves fever, low blood pressure, and potential organ dysfunction. ICANS can cause confusion, difficulty speaking, tremor, and altered consciousness — symptoms that may be especially difficult to evaluate in patients with pre-existing cognitive decline.
Can patients with dementia safely receive bispecific antibody therapy?
There is no blanket contraindication, but the decision requires careful evaluation. The neurotoxicity risk means that baseline cognitive testing, proactive monitoring, and strong caregiver involvement are essential. The appropriateness depends on the severity of cognitive impairment, overall health, and individual goals of care.
How does linvoseltamab differ from teclistamab?
Both target BCMA and CD3, but linvoseltamab offers a dosing advantage — it can be given every two weeks starting at week 14, and every four weeks for patients achieving a very good partial response or better after 24 weeks. Linvoseltamab is currently approved only as monotherapy for patients with four or more prior lines of treatment, while the teclistamab combination is approved after just one prior line.
What new bispecific antibodies are in development for myeloma?
LBL-034, a GPRC5D/CD3-targeting bispecific T-cell engager, has received FDA Fast Track Designation based on early clinical data. Additional agents targeting both BCMA and alternative antigens are in various stages of clinical trials. ASCO has noted a “massive shift” in myeloma treatment driven largely by these immunotherapies.
